Table 1.
Demographic and clinical characteristics of resected pancreatic cancer patients1
| Variable | Category | The US | Belgium | The Netherlands | Slovenia | Norway |
|---|---|---|---|---|---|---|
| Incidence (per 100,000)2 | Male | 8.6 | 7.4 | 7.4 | 9.3 | 7.8 |
| Female | 6.5 | 5.6 | 6.1 | 6.5 | 6.5 | |
| Years of diagnosis | 2004–2015 | 2004–2013 | 2003–2014 | 2003–2013 | 2003–2014 | |
| n | 9519 | 1105 | 982 | 118 | 113 | |
| Diagnosis in 2010 or later | Yes | 5635 (59) | 579 (52) | 747 (76) | 67 (57) | 79 (70) |
| Sex | Female | 4671 (49) | 522 (47) | 483 (49) | 50 (42) | 58 (51) |
| Age (years) | Median (interquartile range) | 65 (58–72) | 65 (58–71) | 64 (57–69) | 61 (54–68) | 63 (59–70) |
| Mean ± standard deviation | 65 ± 10 | 64 ± 10 | 62 ± 9 | 61 ± 9 | 64 ± 8 | |
| < 50 | 706 (7) | 90 (8) | 92 (9) | 11 (9) | 4 (4) | |
| 50–59 | 2101 (22) | 264 (24) | 235 (24) | 38 (32) | 29 (26) | |
| 60–69 | 3464 (36) | 406 (37) | 417 (42) | 46 (39) | 50 (44) | |
| ≥ 70 | 3248 (34) | 345 (31) | 238 (24) | 23 (19) | 30 (27) | |
| Tumor location3 | Pancreas head | 7314 (83) | 658 (82) | 820 (90) | 97 (92) | 91 (88) |
| Pancreas body | 622 (7) | 58 (7) | 31 (3) | 5 (5) | 4 (4) | |
| Pancreas tail | 845 (10) | 86 (11) | 63 (7) | 3 (3) | 8 (8) | |
| Other | 738 (8) | 303 (27) | 68 (7) | 13 (11) | 10 (9) | |
| T stage4 | T1 | 494 (5) | 56 (5) | 72 (7) | 0 (0) | 8 (8) |
| T2 | 1192 (13) | 185 (17) | 182 (19) | 8 (7) | 28 (26) | |
| T3 | 7815 (82) | 860 (78) | 727 (74) | 108 (93) | 70 (66) | |
| N stage5 | N1 | 6339 (67) | 805 (73) | 703 (72) | 97 (84) | 60 (55) |
| Differentiation6 | Well | 858 (10) | 149 (15) | 91 (11) | 12 (11) | 3 (3) |
| Intermediate | 4540 (52) | 511 (52) | 423 (51) | 44 (40) | 64 (63) | |
| Poor/undifferentiated | 3266 (38) | 326 (33) | 319 (38) | 55 (50) | 35 (34) |
1Categorical data are shown as count (percentage [%]). For brevity, results for the counterparts in dichotomous variables are omitted. Records are complete otherwise specified below
2The cancer incidence rates by sex in each country were retrieved from the Cancer Incidence in Five Continents Volume XI (CI5 XI) by the International Agency for Research on Cancer (IARC), World Health Organization (WHO) which reports the incidence of cancers diagnosed from 2008 to 2012, standardized to the World (WHO 2000–2025) Standard Population
3The percentages of pancreas head, body, tail, and overlapping cancers are the proportions compared to the total tumor cases of the four locations; “other” includes overlapping lesion, pancreas duct, and not otherwise specified location, and its proportion is relative to the whole cases
4Missing T stage: the US: 18 (< 1%); Belgium: 4 (< 1%); the Netherlands: 1 (< 1%); Slovenia: 2 (2%); Norway: 7 (6%)
5Missing N stage: the US: 0 (0%); Belgium: 7 (1%); the Netherlands: 0 (0%); Slovenia: 2 (2%); Norway: 3 (3%)
6Missing differentiation: the US: 855 (9%); Belgium: 119 (11%); the Netherlands: 149 (15%); Slovenia: 7 (6%); Norway: 11 (10%)